中药在原发性肝癌介入治疗中作用的研究概况

原发性肝癌(下简称肝癌)是我国常见恶性肿瘤之一,恶性度高,预后差,尤其是大肝癌,目前尚无特效治疗方法。近年来采用中医药配合肝癌介入治疗及以中药介入治疗肝癌取得了一定成效,现就有关文献综述如下。1 中药配合介入治疗的研究 郑氏采用逍遥散加味配合肝动脉插管化疗治疗中晚期肝癌35例,结果完全缓解者3例,部分缓解者24例,稳定者5例,恶化者3例,总有效率77.1％。沈氏等用中药(生米仁、茜草、丹参、仙鹤草、蛇香草、八月札,随症加味)配合DMF方案,肝动脉灌注治疗20例晚期肿瘤,有效率达85％,其中生存6个月以上者19例,1年以上者5例。孙氏等认为肝癌介入     

中西医结合治疗晚期鼻咽癌96例疗效分析

目的：研究中西医结合治疗鼻咽癌放疗后复发和（或）转移患者的疗效。方法：对９６例放疗后复发和（或）转移的鼻咽癌患者给予中药加化疗治疗。化疗方案主要选用ＣＯＭＰ、ＰＢＭ、ＣＡＰ和ＰＦ;中药使用则按辨证论治。结果：治疗后完全缓解（ＣＲ）７例,部分缓解（ＰＲ）３２例,有效率（ＣＲ＋ＰＲ）为４０．６％。患者１年生存率为４９．５％,２年生存率为３３．３％,３年生存率为２４．７％,５年生存率为１５．８％。治疗后有效患者的中位生存期为１９个月,显著长于无效患者的７个月（Ｐ＜０．０１）。结论：中药加化疗对改善晚期鼻咽癌患者的中位生存期和远期生存率有益,对原发灶复发者宜采用ＰＢＭ和ＰＦ方案,对远处转移者选用ＣＯＭＰ、ＣＡＰ方案,可提高疗效。     

恶性肿瘤的中药介入治疗研究概况

介入治疗是将治疗介质经动脉插管插至肿瘤组织,使局部组织的药物浓度较静脉给药或口服高10～30倍,明显减轻全身副作用,并提高疗效。现将近年来中药介入治疗恶性肿瘤的研究概况作一综述,为深入研究作进一步的探讨。     

中药介入治疗原发性肝癌的研究概况及进展

中药介入治疗原发性肝癌的研究概况及进展程剑华，刘新洪原发性肝癌恶性程度高，疾病发展变化快，预后极差。据世界卫生组织最新的统计，全世界每年新增加的６００万癌症患者中，原发性肝癌约占４３万．我国每年死于肝癌的可统计人数已超过１０万。目前手术切除仍然是肝癌...     

COMP与PBM化疗方案治疗晚期鼻咽癌的疗效分析

我们以ＣＴＸ＋ＶＣＲ＋ＭＴＸ＋ＤＤＰ（ＣＯＭＰ）和ＤＤＰ＋ＢＬＭ＋ＭＴＸ（ＰＢＭ）两种化疗方案治疗复发和转移的晚期鼻咽癌５８例，４９例可评价客观疗效。结果ＣＯＭＰ组取得了ＣＲ３例，ＰＲ９例，有效率（ＣＲ＋ＰＲ）为５２．２％；ＰＢＭ组ＣＲ１例，ＰＲ９例，有效率（ＣＲ＋ＰＲ）为３８．５％。两者无显著性差异（Ｐ〉０．０５）。治疗后有效病例缓解期为５～５６月，中位缓解期为２５月。两种方案对鼻咽癌肺转移均较     

健脾益气利水汤预防和治疗化疗肾毒笥的临床研究

将９５例使用高剂量顺铂治疗肿瘤患者随机分为中药预防组和水化对照组，用多项指标观察不同药物对肾功能的影响。结果表明中药组治疗后血ＢＵＮ，血Ｃｒ，血β２－ｍ，尿ＮＡＧ下降，两组疗后的ＢＵＮ，Ｃｒ差异有显著性，中药健腺益气利水汤预防高剂量顺铂肾毒性疗效优于水化组。用此方治疗化疗性肾衰４０例，总有效率为９３．１８％，治疗前后ＢＵＮ，Ｃｒ有非常显著差异。临床研究表明中药健腺益气利水汤具有预防和治疗化疗肾毒性     

益心补气胶囊治疗阿霉素所致心脏毒性31例疗效观察

目的:观察益心补气胶囊治疗阿霉素所致心脏毒性的疗效。方法:对31例阿霉素所致心脏毒性患者使用益心补气胶囊(组成:人参、黄芪、制附子、三七、麦冬、灵芝)治疗,每次6粒,每天3次,连服1周。结果:治疗后绝大部分病例(26/31)心电图恢复正常,与治疗前比较,差异有非常显著性意义(P<0.01);治疗后心酶谱各项指标均明显下降,CK、CK-MB、LDH与治疗前比较,差异有显著性意义(P<0.05)。结论:益心补气胶囊治疗阿霉素所致心脏毒性有较好疗效,可以明显改善和减轻心肌损害。     

A clinical study on global TCM therapy in treating senile advanced non-small cell lung cancer

Objective:To assess the clinical efficacy of global traditional Chinese medicine(TCM) therapy in treating senile advanced non-small cell lung cancer(NSCLC),with the aim of seeking a standardized,rational and economical way to treat advanced NSCLC in old patients.Methods:A retrospective analysis and comparison was carried out in 86 patients with senile advanced NSCLC, 44 treated by global TCM(TCM group)and 42 by chemotherapy(control group)through dynamical observation on related indexes including tumor size,quality of life and the survival time,as well as on the fee for medical service at various time points in the course of the treatment.Results:The changes of tumor size,score of clinical main symptoms and behavior condition(by ZPS scoring),as well as survival rates in the two groups at corresponding time points,were not different significantly(P>0.05). The mean survival time in the TCM group was 13.20±1.52 months and that in the chemotherapy group was 13.45±1.94 months,showing insignificant difference between them.However,the median survival time in the TCM group(12 months)was actually longer than that in the chemotherapy group (9 months,P<0.05).The mean daily expense and the mean expense(RMB yuan)for each patient in the TCM group were significantly lower than that in the control group,which was 180.73±93.21 vs 825.84±329.63 for the mean daily expense and 34 077.21±14 638.04 vs 58 516.59±45 429.76 for the mean expense for each patient(both P<0.01).Conclusion:Treatment of senile advanced NSCLC with TCM alone has its apparent superiority in stabilizing tumor focus,improving clinical symptoms, elevating quality of life and prolonging the survival time.TCM is also less expensive,making it a good alternative therapeutic approach for this specific group of people.     

Development in the Interventional Herbal Treatment of Primary Liver Cancer

Primarylivercancer(PLC)isakindofhighlymalignant,rapidlyprogressivecancerwithpoorprognosis.AccordingtotheWorldHealthOrganization,amongtheyearly6millioncasesofcancer,PLCaccountsfor0.43millioncases.InChina,morethan100thousandpatientsdiedofPLCannually.Sofar,surgicalremovalofthetumorisstillthebesttherapeuticmethod.Unfortunately,mostofthePLCpatientswerediagnosedatthelatestageofthedisease,andcouldonlybetreatedwithconservativemethods.MuchprogresshasbeenmadeintherecentyearsinthetreatmentofPLCwi…